{"output": [["PTC Therapeutics, Inc.", "COMP", "Provide", "Corporate Update", "EVENT"], ["Stuart W. Peltz, Ph.D.", "PERSON", "Highlight", "Companys Presentation", "EVENT"], ["PTC Therapeutics, Inc.", "COMP", "Operate_In", "NASDAQ", "ORG/REG"], ["Translarna\u2122", "PRODUCT", "Treat", "Nonsense Mutation Duchenne Muscular Dystrophy", "CONCEPT"], ["Translarna\u2122", "PRODUCT", "Achieve", "Upper End of Guidance", "CONCEPT"], ["Translarna\u2122", "PRODUCT", "Net Product Revenue", "145 Million", "ECON_INDICATOR"], ["EMFLAZA\u2122", "PRODUCT", "Treat", "Duchenne Muscular Dystrophy", "CONCEPT"], ["EMFLAZA\u2122", "PRODUCT", "Net Product Revenue", "29 Million", "ECON_INDICATOR"], ["PTC Therapeutics, Inc.", "COMP", "Anticipate", "Full-Year Net Product Revenues", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Anticipate", "Translarna Net Product Revenue", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Project", "5-Year Compound Annual Growth Rate", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Anticipate", "EMFLAZA Net Product Revenue", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Anticipate", "GAAP R&D and SG&A Expense", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Anticipate", "Non-GAAP R&D and SG&A Expense", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Plan", "Continued Growth of Translarna Product Revenue", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Expand", "Innovative Pipeline", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Host", "Analyst Day", "EVENT"], ["PTC Therapeutics, Inc.", "COMP", "Use", "Non-GAAP Financial Measures", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Assess", "Operational Trends", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Identify", "Operational Trends", "CONCEPT"], ["PTC Therapeutics, Inc.", "COMP", "Exclude", "Non-Cash Stock-Based Compensation Expense", "CONCEPT"]], "published": "2018-01-08T16:00:00.000+02:00"}